top of page
Hypha News
Stay up-to-date throughout the year with all of the latest news and updates happening at Hypha Wellness. From exciting announcements for the upcoming season to news about our efforts to make advancements in the industry, you’ll find it all here.
Jamaica’s mountainous peaks and emerald water beaches aren’t the only reason people call this Caribbean Island nation paradise. It’s also home to numerous psychedelic retreats. Psilocybin mushrooms are legal there, and Havn Life Sciences is using this opportunity to launch a psilocybin cultivation facility on the island.
“Growing regulated psilocybin mushrooms for medical research is a very complex process. Our Jamaican collaborations are expected to allow us to optimize and refine our processes faster than we could elsewhere,” says Dr. Ivan Casselman, chief psychedelic officer of the psychedelic biotech company Havn Life Sciences. “Most importantly, they’re expected to better facilitate Havn Life’s commitment to helping patients, specifically those participating in observational studies in Jamaica.”
Havn Life entered into a partnership with Hypha Wellness Jamaica Psilocybin (HWJP) to research and develop a supply chain for the regulated production of psilocybin medicine for therapeutic use. The companies are slated to develop standardized powdered, homogenized, psilocybin mushroom products for academic research around the world before the end of 2021. Havn Life is focused on supporting future clinical trials using psilocybin to address post-traumatic stress disorder and other trauma-related disorders.
VANCOUVER, BC / May 4, 2021/
Havn Life, a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it now has a fully operational mycology lab and production facility in Jamaica.
By operationalizing the facility, the Company's research division, Havn Labs, has begun production alongside local partner Hypha Wellness, a Jamaican-based food and psychoactive mushroom producer. This puts the Company on track to deliver naturally-derived psilocybin products to clinical studies and researchers by Q4 2021
Canadian biotechnology company Havn Life Sciences Incorporated has signed a letter of intent with local nutraceutical firm Hypha Wellness Jamaica Psilocybin to research and produce safe, quality-controlled medicine from mushrooms (psilocybin medicine).
Headquartered in Kingston, Hypha Wellness is focused on the cultivation, extraction, and manufacturing of nutraceuticals and is positioned to explore and optimise the therapeutic and commercial potentials of psilocybin and other fungi for local and international markets.
This deal involves the two partners jointly researching and coming up with standardized powdered homogenizedpsilocybin mushroom active pharmaceutical ingredient (API) products.
This partnership will be compliant to all regulatory requirements and will observe all applicable regulations in producing the powdered API products.
bottom of page